Isoptin

Verapamil, the active ingredient in Isoptin, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure, chest pain due to angina, and certain cardiac rhythm disorders in adult patients, and is commonly prescribed by cardiologists and primary care physicians.

GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Isoptin (verapamil) is used to treat conditions related to cardiovascular pressure regulation and cardiac electrical activity.

Hypertension: helps lower systemic arterial pressure by causing vasodilation of peripheral blood vessels, thereby reducing cardiac workload. Angina pectoris: diminishes frequency and severity of chest pain by decreasing myocardial oxygen consumption through reduced contractility and heart rate. Supraventricular tachycardia and other cardiac arrhythmias: controls abnormal rapid heart rhythms by slowing conduction through the atrioventricular node and extending refractory periods. Atrial fibrillation: assists in rate control by reducing ventricular response through AV nodal blockade, improving symptoms and preventing tachycardia-mediated cardiomyopathy.

Verapamil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Dizziness: transient light‑headedness often related to blood pressure changes. - Headache: mild to moderate pain commonly reported during therapy initiation. - Peripheral edema: swelling of ankles or lower limbs due to vasodilation. - Nausea: upset stomach with possible vomiting. - Flushing: transient warmth and reddening of skin.

Serious or Rare Side Effects: - Severe bradycardia: markedly slowed heart rate that may require medical attention. - Heart block: impairment of electrical conduction between atria and ventricles. - Hypotension: significant drop in blood pressure causing faintness or shock.

Before initiating verapamil therapy, clinicians should consider several safety aspects. - Cardiovascular monitoring: assess heart rate and blood pressure before and during therapy. - Conduction disorders: avoid in patients with existing AV block unless paced. - Liver impairment: use with caution; dose adjustment may be required. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Verapamil interacts with several medicines; careful review is essential.

Major Interactions (Avoid): - Beta‑blockers: combined use may cause excessive bradycardia or AV block. - Digoxin: increased serum levels leading to toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise verapamil concentrations. - Macrolide antibiotics (e.g., erythromycin): may increase plasma levels.

Moderate Interactions (Monitor Closely): - Diltiazem: additive effects on cardiac conduction. - Rifampin: may reduce verapamil effectiveness. - NSAIDs: can diminish antihypertensive effect. - Calcium supplements: may reduce absorption; separate dosing by at least 2 hours. - Other antihypertensives: monitor for additive blood pressure lowering.